{
    "guideline": {
        "id": "PA166262241",
        "name": "Annotation of CPIC Guideline for lovastatin and SLCO1B1",
        "source": "CPIC",
        "version": 5,
        "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166262241",
        "relatedChemicals": [
            {
                "id": "PA450272",
                "name": "lovastatin",
                "symbol": null
            }
        ],
        "relatedGenes": [
            {
                "id": "PA134865839",
                "name": "solute carrier organic anion transporter family member 1B1",
                "symbol": "SLCO1B1"
            }
        ],
        "recommendation": true
    },
    "recommendations": [
        {
            "id": "PA166298192",
            "name": "Recommendation PA166298192",
            "population": "general",
            "classification": {
                "term": "No recommendation",
                "termId": "guidelineStrength:1448526251"
            },
            "relatedChemicals": [
                {
                    "id": "PA450272",
                    "name": "lovastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060794,
                "html": "<p>No recommendation</p>\n"
            },
            "implications": [
                "SLCO1B1: n/a"
            ],
            "lookupKey": {
                "SLCO1B1": "Indeterminate"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298148",
            "name": "Recommendation PA166298148",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450272",
                    "name": "lovastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060750,
                "html": "<p>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
            },
            "implications": [
                "SLCO1B1: Typical myopathy risk and statin exposure"
            ],
            "lookupKey": {
                "SLCO1B1": "Increased Function"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298189",
            "name": "Recommendation PA166298189",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450272",
                    "name": "lovastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060791,
                "html": "<p>Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to \u226420mg/day.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
            },
            "implications": [
                "SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk"
            ],
            "lookupKey": {
                "SLCO1B1": "Possible Decreased Function"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166297982",
            "name": "Recommendation PA166297982",
            "population": "general",
            "classification": {
                "term": "Strong",
                "termId": "guidelineStrength:981501930"
            },
            "relatedChemicals": [
                {
                    "id": "PA450272",
                    "name": "lovastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060584,
                "html": "<p>Prescribe desired starting dose and adjust doses based on disease-specific guidelines.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function and ancestry should be evaluated prior to initiating a statin.</p>\n"
            },
            "implications": [
                "SLCO1B1: Typical myopathy risk and statin exposure"
            ],
            "lookupKey": {
                "SLCO1B1": "Normal Function"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": false,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "1"
        },
        {
            "id": "PA166298190",
            "name": "Recommendation PA166298190",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450272",
                    "name": "lovastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060792,
                "html": "<p>Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to \u226420mg/day.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
            },
            "implications": [
                "SLCO1B1: Increased lovastatin acid exposure as compared to normal function which may translate to increased myopathy risk"
            ],
            "lookupKey": {
                "SLCO1B1": "Decreased Function"
            },
            "dosingInformation": true,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        },
        {
            "id": "PA166298191",
            "name": "Recommendation PA166298191",
            "population": "general",
            "classification": {
                "term": "Moderate",
                "termId": "guidelineStrength:981501931"
            },
            "relatedChemicals": [
                {
                    "id": "PA450272",
                    "name": "lovastatin",
                    "symbol": null
                }
            ],
            "text": {
                "id": 1452060793,
                "html": "<p>Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins).</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The potential for drug-drug interactions and dose limits based on renal and hepatic function should be evaluated prior to initiating a statin. The effects of drug-drug interactions may be more pronounced resulting in a higher risk of myopathy.</p>\n"
            },
            "implications": [
                "SLCO1B1: Increased lovastatin acid exposure as compared to normal and decreased function which may translate to increased myopathy risk"
            ],
            "lookupKey": {
                "SLCO1B1": "Poor Function"
            },
            "dosingInformation": false,
            "alternateDrugAvailable": true,
            "otherPrescribingGuidance": false,
            "guidanceLevel": "2"
        }
    ],
    "citations": [
        {
            "pmid": "35152405",
            "title": "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.",
            "authors": [
                "Cooper-DeHoff Rhonda M",
                "Niemi Mikko",
                "Ramsey Laura B",
                "Luzum Jasmine A",
                "Tarkiainen E Katriina",
                "Straka Robert J",
                "Gong Li",
                "Tuteja Sony",
                "Wilke Russell A",
                "Wadelius Mia",
                "Larson Eric A",
                "Roden Dan M",
                "Klein Teri E",
                "Yee Sook Wah",
                "Krauss Ronald M",
                "Turner Richard M",
                "Palaniappan Latha",
                "Gaedigk Andrea",
                "Giacomini Kathleen M",
                "Caudle Kelly E",
                "Voora Deepak"
            ],
            "journal": "Clinical pharmacology and therapeutics",
            "year": 2022
        }
    ],
    "version": "2024-03-25-16-13"
}